Parkman Healthcare Partners LLC Acquires Shares of 50,672 Alnylam Pharmaceuticals, Inc. $ALNY

Parkman Healthcare Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 2nd quarter, Holdings Channel reports. The institutional investor bought 50,672 shares of the biopharmaceutical company’s stock, valued at approximately $15,254,000. Alnylam Pharmaceuticals comprises about 1.6% of Parkman Healthcare Partners LLC’s investment portfolio, making the stock its 25th biggest holding.

A number of other large investors also recently made changes to their positions in ALNY. Legal & General Group Plc acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $278,321,000. Brandywine Managers LLC acquired a new position in Alnylam Pharmaceuticals in the second quarter valued at about $698,000. L2 Asset Management LLC acquired a new position in Alnylam Pharmaceuticals in the second quarter valued at about $231,000. Cibc World Market Inc. bought a new position in Alnylam Pharmaceuticals during the second quarter worth about $2,174,000. Finally, OMERS ADMINISTRATION Corp bought a new position in Alnylam Pharmaceuticals during the second quarter worth about $1,360,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Wells Fargo & Company lowered their price target on Alnylam Pharmaceuticals from $316.00 to $256.00 and set an “equal weight” rating for the company in a research note on Friday, August 14th. JPMorgan Chase & Co. decreased their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Oppenheimer lowered their target price on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Truist Financial cut their target price on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating on the stock in a report on Tuesday, August 4th. Finally, Wall Street Zen cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 2nd. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $386.14.

Alnylam Pharmaceuticals Trading Down 0.1%

NASDAQ:ALNY opened at $236.01 on Tuesday. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The business’s 50-day simple moving average is $265.98 and its 200-day simple moving average is $296.21. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $197.81 and a fifty-two week high of $495.55. The stock has a market capitalization of $31.58 billion, a PE ratio of 43.87 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. The business had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.Alnylam Pharmaceuticals’s revenue for the quarter was up 66.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.51) EPS. Sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current fiscal year.

Insider Activity

In other news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares of the company’s stock, valued at $473,302.76. This represents a 70.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.